Edition:
United States

JCR Pharmaceuticals Co Ltd (4552.T)

4552.T on Tokyo Stock Exchange

3,325JPY
22 Sep 2017
Change (% chg)

¥255 (+8.31%)
Prev Close
¥3,070
Open
¥3,215
Day's High
¥3,340
Day's Low
¥3,115
Volume
416,800
Avg. Vol
128,923
52-wk High
¥3,340
52-wk Low
¥2,133

Chart for

About

JCR Pharmaceuticals Co., Ltd. is a Japan-based company primarily engaged in the pharmaceutical business, as well as the medical and research equipment business. The Pharmaceutical business engages in the research, production, purchase and sale of medical drugs and pharmaceutical raw materials. The Medical and Research Equipment... (more)

Overall

Beta: 1.18
Market Cap(Mil.): ¥107,801.70
Shares Outstanding(Mil.): 32.42
Dividend: 11.00
Yield (%): 0.66

Financials

  Industry Sector
P/E (TTM): -- 31.67 16.08
EPS (TTM): -- -- --
ROI: -- 15.12 14.60
ROE: -- 16.35 14.03

BRIEF-JCR Pharmaceuticals completes share repurchase through ToSTNeT-3

* Says it completed repurchase of 854,100 shares of its common stock, for 2.62 billion yen in total, through ToSTNeT-3, on Sept. 22

Sep 21 2017

BRIEF- JCR Pharmaceuticals to repurchase shares

* Says it will repurchase up to 940,000 shares of its common stock, representing 2.7 percent of outstanding, on Sept. 22

Sep 21 2017

BRIEF- JCR Pharmaceuticals announces shareholding structure change

* Says its top shareholder GLAXO GROUP LIMITED will cut voting power in the company to 0 percent from 25.2 percent

Sep 21 2017

BRIEF- JCR Pharmaceuticals announces business and capital alliance with Medipal Holdings

* Says it signed a business and capital alliance with Medipal Holdings Corp

Sep 21 2017

BRIEF- JCR Pharmaceuticals to develop allogeneic regenerative medical product using DPCs with Teijin

* Says it entered into co-development and license agreement with Teijin Ltd, regarding JTR-161, an allogeneic regenerative medical product using dental pulp stem cells (DPCs) for the indication of acute cerebral infarction (stroke) for Japan, on July 18

Jul 18 2017

BRIEF-JCR Pharmaceuticals to dissolve Hebei-based subsidiary

* Says it plans to dissolve Hebei province-based subsidiary, which is engaged in pharmaceutical business

Apr 26 2017

BRIEF-JCR Pharmaceuticals initiates phase 1/2 clinical trial of jr-141 in hunter syndrome

* Says co initiates phase 1/2 clinical trial of jr-141 in hunter syndrome

Mar 31 2017

Earnings vs. Estimates